Karen L. Reckamp, MD

Karen L. Reckamp, MD, director, Medical Oncology, associate director, Clinical Research, and Medical Oncology director, Lung Institute at Samuel Oschin Cancer Center, discusses the current limitations with standard of care treatment for patients with non–small cell lung cancer (NSCLC).

In the phase 2 Lung-MAP substudy S1800A (NCT03971474), the combination of pembrolizumab (Keytruda) and ramucirumab (Cyramza) was evaluated in patients with stage IV, previously-treated advanced NSCLC who acquired resistance to immune checkpoint inhibitors (ICI). Acquired resistance in the study was defined as previous ICI therapy for at least 84 days with progressive disease on or after therapy.

Reckamp also provides an overview on what makes the combination of ramucirumab and pembrolizumab a promising option for this patient population.

 The limitations of standard of care are really that the combination of ramucirumab and docetaxel was approved in about 2014. This has been the only standard in addition to single-agent chemotherapy for patients who have had tumor growth on chemotherapy and immune checkpoint inhibitor therapy.

We really are at a point where we need some novel therapies, novel combinations, and uniquely ramucirumab/pembrolizumab is a non-chemotherapy option for patients. That's 1 way that makes this combination exciting.

Videos

Karen L. Reckamp, MD, discusses the current limitations with standard of care treatment for patients with non–small cell lung cancer.


Limitations With Standard of Care in ICI-Pretreated Patients With NSCLC

Karen L. Reckamp, MD, co-director, Lung Cancer and Thoracic Oncology Program, associate professor, City of Hope, discusses a phase II, single-arm study of cabozantinib plus erlotinib for the treatment of patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC).

Learn more about the combination of cabozantinib and erlotinib for NSCLC > >

Articles

Karen L. Reckamp, MD, discusses a phase II, single-arm study of cabozantinib plus erlotinib for the treatment of patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC).

Cabozantinib Plus Erlotinib for Advanced EGFR-Mutant NSCLC

Karen L. Reckamp, MD, co-director, Lung Cancer and Thoracic Oncology Program, associate professor, City of Hope, discusses the results of a phase II study of the AKT inhibitor MK-2206 plus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) who progressed on erlotinib.

There were two cohorts on this study. The first cohort contained patients who were EGFR wild- type and had previously responded to EGFR TKI therapy for at least 12 weeks while the other cohort contained EGFR mutated patients who had responded to EGFR TKI therapy for at least 12 weeks.

An improvement in disease control rate was found in the first cohort when patients were treated with MK-2206 plus erlotinib.

There was not a significant improvement in response or disease control rate in the EGFR mutant group.

This combination may improve de novo resistance and may be helpful for patients with EGFR wild-type tumors.

Karen L. Reckamp, MD, co-director, Lung Cancer and Thoracic Oncology Program, associate professor, City of Hope, the results of a phase II study of the AKT inhibitor MK-2206 plus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) who progressed on erlotinib.

Karen L. Reckamp, MD | Authors

Articles

Limitations With Standard of Care in ICI-Pretreated Patients With NSCLC

Cabozantinib Plus Erlotinib for Advanced EGFR-Mutant NSCLC

An Analysis of a Phase II study MK-2206 plus Erlotinib in NSCLC